Shenzhen Capital Group Leads $28M Series B Round In Biotech Hrain Biotechnology

Shanghai-based oncotherapy-focused firm Hrain biotechnology Co., Ltd. announces on Monday that it raises RMB200 million (US$28 million) in a series B funding round led by venture capital firm Shenzhen Capital Group (SCG).

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets

LEAVE A REPLY